2seventy bio to Participate in CG Horizons in Oncology Virtual Conference

On April 7, 2022 2seventy bio, Inc. (Nasdaq: TSVT) reported that it will present at the CG Horizons in Oncology Virtual Conference, on the Attacking AML: New Approaches Panel on Thursday, April 14, 2022 at 1:30pm ET (Press release, 2seventy bio, APR 7, 2022, View Source [SID1234611586]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

Live webcasts of presentations will be available via the Investors and Media section of 2seventy bio’s website at View Source A replay of each presentation will be archived on 2seventy bio’s site for 30 days following the event.

Use the contact form at the top or bottom of this page to book a free demo to 1stOncology™, an all inclusive cancer drug development intelligence platform from BioSeeker. The platform provides value in oncology for you in areas such as:

Target scouting
Indication selection & expansion
Combinatorial drug settings
Drug repositioning
First in class analysis
Compound cross over analysis
Competitive analysis
Pathway analysis

and much more...

1stOncology is recognized as a
Top 10 Global Pharma Analytic Provider

Continue your journey with 1stOncology by accessing our Free Leading Cancer Conference Whitepapers, signing up for our Free Weekly Newsletter and requesting a Free Demo to see how we can help you be 1st in Oncology!